Skip to main
ILMN
ILMN logo

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 7%
Buy 29%
Hold 50%
Sell 7%
Strong Sell 7%

Bulls say

Illumina's clinical consumables revenue exhibited a mid-single-digit year-over-year increase, signaling a positive trend in the company's core business. The continued success of the MiSeq i100 Plus in attracting new-to-sequencing customers further underscores Illumina's growth potential within the sequencing market. Additionally, the company's increased non-GAAP diluted EPS guidance, now ranging from $4.45 to $4.55, reflects strong operational momentum and favorable funding conditions.

Bears say

Illumina's outlook appears negative primarily due to anticipated revenue declines, with projections indicating a decrease of 1.5-2.5% year-over-year for 3Q25, resulting in reported revenue guidance of approximately $1.06-1.07 billion. Additionally, the company is experiencing a significant contraction in its instruments segment, expecting a y/y revenue decline of 4-6% while only modest growth of 1-3% is expected in sequencing consumables, excluding China. The recent drop in NovaSeq X shipments compared to both the previous quarter and the same period in the prior year further underscores the challenges Illumina faces in maintaining sales momentum.

Illumina (ILMN) has been analyzed by 14 analysts, with a consensus rating of Hold. 7% of analysts recommend a Strong Buy, 29% recommend Buy, 50% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Hold based on their latest research and market trends.

According to 14 analysts, Illumina (ILMN) has a Hold consensus rating as of Dec 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $117.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $117.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.